Tag Archive for: prostate cancer
Matching-Adjusted Comparison of PARPi Therapies for mCRPC: Talazoparib + Enzalutamide Wins
/in Clinical Trial, Metastatic, Observational, Post-hoc, Retrospective studies/by MaxAPVO442: A Promising New Bispecific Antibody for Prostate Cancer Treatment
/in Preclinical Research/by MaxMetformin Shows Promise in Reducing Side Effects of Hormone Therapy in Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxJanux Therapeutics Announces 100% Response in Phase 1a Results for JANX007 in mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxInhibition of SREBP Reinduces Docetaxel Sensitivity in Advanced Prostate Cancer
/in Preclinical Research/by MaxKaempferol: A Potential Treatment for Emotional Stress-Aggravated Prostate Cancer Metastasis
/in Preclinical Research/by MaxTruqap Shows Promise in Treating a Subtype of Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Phase 1 Trial: JANX007 Plus JANX013 Combo in mCRPC / mAPMR September 14, 2026
- CRISPR Takes Another Step Forward September 14, 2026
- A STEAP1 ADC That May Turn Tumour Killing Into an Immune Response September 14, 2026
- Soon to be Phase 1 for ICP-B381, a New Bispecific Antibody-Drug Conjugate for mCPRC September 14, 2026